Skip to main content
    G

    Genelux Corporation Common Stock (GNLX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.92
    +0.06 (+2.95%)

    Market Cap: $84.38M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Genelux Corporation Common Stock (GNLX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 11, 2026. Financial statements from company filings, amounts in US dollars.

    Genelux Corporation Common Stock reported revenue of $8.00K for the fiscal year ended Dec 31, 2025, unchanged at 0.0% from the year before. That year, net income was -$32.15M with a net margin of -401812.5%, operating cash flow was -$25.27M and free cash flow was -$26.37M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$10.29M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$8.00K0.0%100.0%-415175.0%-401812.5%
    Dec 2024$8.00K-95.3%100.0%-396200.0%-373362.5%
    Dec 2023$170.00K-98.5%100.0%-14214.7%-16645.3%
    Dec 2022$11.07MN/A100.0%-27.2%-47.0%
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$8.00K$8.00K$170.00K$11.07M$0$0N/A
    Cost of revenue$0$0$0$0$895.00K$658.00K$477.00K
    Gross profit$8.00K$8.00K$170.00K$11.07M-$895.00K-$658.00K-$477.00K
    Research and development$19.85M$19.00M$12.77M$9.08M$6.32M$6.23M$7.53M
    Operating income-$33.21M-$31.70M-$24.16M-$3.01M-$14.61M-$12.42M-$10.87M
    Net income-$32.15M-$29.87M-$28.30M-$5.21M-$17.80M-$14.86M-$11.63M
    EBITDA-$32.61M-$30.33MN/A-$1.89M-$13.67M-$11.76M-$10.49M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$8.00K$0$0$0$896.00K$0$0$8.00K$1.46M
    Gross profit$0$0$0$8.00K$0$0$0-$227.00K$0$0$8.00K-$201.00K
    Operating income-$10.40M-$9.64M-$9.17M-$9.41M-$8.19M-$7.79M-$7.82M-$9.75M-$6.94M-$6.89M-$8.12M-$7.00M
    Net income-$10.29M-$9.47M-$8.93M-$9.25M-$7.95M-$7.46M-$7.49M-$8.98M-$6.47M-$6.58M-$7.85M-$6.77M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $427.00K by $4.91M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$19.03M$34.72M$27.89M$5.53M$8.13M$14.01M$3.28M
    Current assets$15.13M$31.55M$24.20M$1.89M$5.82M$11.48M$551.00K
    Cash and equivalents$5.33M$8.56M$9.42M$397.00K$4.50M$11.35M$425.00K
    Total liabilities$7.48M$8.44M$8.42M$41.31M$41.24M$36.66M$28.09M
    Short-term debt$427.00K$329.00K$1.31M$16.40M$6.56M$3.89M$4.61M
    Long-term debtN/AN/AN/A$8.52M$18.02M$21.69MN/A
    Shareholder equity$11.54M$26.27M$19.47M-$35.78M-$33.11M-$22.66M-$24.81M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$20.61M$26.20M$32.37M$19.03M$24.99M$32.25M$38.98M$34.72M$40.27M$45.18M$24.68M$27.89M
    Total liabilities$11.43M$10.09M$9.45M$7.48M$6.40M$8.35M$9.14M$8.44M$7.18M$7.51M$9.59M$8.42M
    Cash and equivalents$9.45M$9.18M$9.27M$5.33M$3.69M$6.55M$16.21M$8.56M$6.10M$7.86M$4.06M$9.42M
    Shareholder equity$9.18M$16.11M$22.92M$11.54M$18.59M$23.90M$29.85M$26.27M$33.09M$37.67M$15.08M$19.47M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$25.27M-$21.23M-$20.27M-$3.57M-$6.58M-$7.21M-$7.22M
    Capital expenditures$1.10M$381.00K$1.02M$49.00K$49.00K$20.00K$1.77M
    Free cash flow-$26.37M-$21.61M-$21.30M-$3.62M-$6.63M-$7.22M-$8.99M
    Investing cash flow$12.14M-$8.13M-$14.72M-$49.00K-$49.00K-$20.00K-$1.77M
    Financing cash flow$9.89M$28.51M$44.02M-$478.00K-$270.00K$18.15M$7.89M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$5.93M-$6.44M-$6.06M-$6.20M-$6.58M-$7.06M-$5.43M-$4.30M-$5.75M-$6.82M-$4.35M-$6.91M
    Capital expenditures$2.72M$1.53M$921.00K$436.00K$517.00K$115.00K$30.00K$96.00K$27.00K$228.00K$30.00K$243.00K
    Free cash flow-$8.65M-$7.98M-$6.98M-$6.63M-$7.09M-$7.17M-$5.46M-$4.40M-$5.78M-$7.05M-$4.38M-$7.15M
    Last 12 quarters

    Frequently Asked Questions About GNLX

    What is Genelux Corporation Common Stock's annual revenue?

    Genelux Corporation Common Stock reported revenue of $8.00K for the fiscal year ended Dec 31, 2025.

    How fast is Genelux Corporation Common Stock's revenue growing?

    Revenue was unchanged at 0.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -91.0%.

    Is Genelux Corporation Common Stock profitable?

    No. Genelux Corporation Common Stock reported net income of -$32.15M for the fiscal year ended Dec 31, 2025, with a net margin of -401812.5%.

    How much free cash flow does GNLX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$25.27M minus capital expenditures of $1.10M produced free cash flow of -$26.37M.

    How much debt does Genelux Corporation Common Stock have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $427.00K and cash and equivalents of $5.33M.